The addition of evolocumab to a statin regimen was found to lower the risk for complex coronary disease requiring revascularization in patients with stable atherosclerosis.
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.
A combination of statin and ezetimibe vs statin alone was found to further reduce levels of LDL-C in patients at very high cardiovascular risk.
Multimodal lipid lowering therapy may be regularly adjusted in patients with bi-allelic familial hypercholesterolemia based on ultrasounds of all accessible arteries.
Comprehensive control of multiple cardiovascular risk factors in high-risk patients was found to be suboptimal worldwide.
Adverse pregnancy outcomes, particularly hypertensive disorders of pregnancy and low birth weight, may be risk factors for atherosclerotic cardiovascular disease.
Patients with very low levels HDL-cholesterol did not have improvements in carotid wall inflammation or dimensions when treated with an HDL mimetic.
The platelet to lymphocyte ratio may aide in stratifying risk in coronary artery disease.
Evolocumab treatment in addition to statin therapy was found to lower cardiovascular risk in patients with metabolic syndrome and stable atherosclerotic cardiovascular disease.
Researchers sought to examine the safety of aspirin as a primary prevention method for atherosclerotic cardiovascular events in high-risk patients.
